Despite decades of experience with hematopoietic stem cell transplantation, we are still faced with the delicate equipoise of achieving stable ocular health post-transplantation. This is because ocular graft-versus-host disease (oGvHD) following hematopoietic stem cell transplantation frequently occurs (≥50%) among transplant patients. To date, our understanding of the pathophysiology of oGvHD especially the involvement of the meibomian gland is still limited as a result of a lack of suitable preclinical models among other. Herein, the current state of the etiology and, pathophysiology of oGvHD based on existing pre-clinical models are reviewed. The need for additional pre-clinical models and knowledge about the involvement of the meibomian glands in oGvHD are emphasized.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036656 | PMC |
| http://dx.doi.org/10.3390/ijms22073516 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.
Neuro Oncol
January 2025
Childhood Cancer & Cell Death team (C3 team), Consortium South-ROCK, LabEx DEVweCAN, Institut Convergence Plascan, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France.
Background: Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic strategies. In the past decades, patient-derived tumor organoids (PDT-O) have emerged as powerful tools for modeling tumoral cell diversity and dynamics, and they could then help defining new therapeutic options for pediatric brain tumors.
View Article and Find Full Text PDFBackground: Intrathecally (IT) delivered antisense oligonucleotides (ASOs) are promising therapies that can reduce tau pathology in Alzheimer's Disease (AD). However, current plasma and CSF sampling methods to estimate brain tissue exposure of ASOs are inherently limited, hampering ASO clinical developmental plans. We developed the PET tracer [F]BIO-687, which binds ASO conjugates (ASO-Tz) in vivo, allowing us to image ASO distribution in a living brain using "pretargeted" imaging.
View Article and Find Full Text PDFBackground: Tau protein tangles have been recently shown to accumulate in multiple brainstem nuclei in pre-cortical Alzheimer's disease (AD) stages. The impact of neurotransmission alterations on brain atrophy and their genetic correlates in AD remain unexplored. Therefore, the aims of this study were: 1) to investigate associations between grey matter (GM) loss across the AD continuum and the distribution of multiple neurotransmitter receptors/transporters; 2) to investigate the impact of polygenic risk scores for AD (PRSs) on such associations.
View Article and Find Full Text PDFBackground: A multi-center study in Los Angeles (USC), Kansas City (KUMC) and Dallas (UT-SWMC) quantified via predictive modeling the dynamics of cerebral perfusion regulation (CO2 vasoreactivity and cerebral autoregulation) in MCI/AD patients and cognitively normal controls under resting conditions. The goal was to develop model-based physio-markers for accurate diagnosis of MCI and pre-clinical AD, motivated by our previous findings of significant impairment of cerebral perfusion regulation in MCI and mild AD patients.
Method: Continuous spontaneous changes in arterial blood pressure, end-tidal CO2, cerebral blood flow velocity in middle cerebral arteries and cortical tissue oxygenation at lateral prefrontal cortex were recorded over two 6-8 min sessions, separated by session of slow-paced breathing (6 breaths/minute), in 53 MCI (28 APOE4 non-carriers and 25 APOE4 carriers), 33 mild AD patients (13 APOE4 non-carriers and 20 APOE4 carriers) and 74 age/sex-matched cognitively normal controls (50 APOE4 non-carriers and 24 APOE4 carriers).
Biomarkers.
Alzheimers Dement
December 2024
Texas Children's Hospital/Baylor College of Medicine, Houston, TX, USA.
Background: Clinical studies in COVID-19 patients have demonstrated evidence of neuroinflammation in patients infected with SARS-CoV-2. In this pre-clinical work, we investigate neuroinflammation in vivo in a mouse model of Alzheimer's disease (AD) that exhibits both amyloid and tau pathology, the 3xTg-AD mice crossed with K18 hAce2 and infected with SARS-CoV-2 using a folate receptor-targeted nanoprobe for molecular MRI (mMRI) followed by ex vivo histopathology.
Method: In vivo studies with SARS-CoV-2 were performed in an animal biosafety level 3 (ABSL3) facility.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!